Literature DB >> 20131028

Could we use clinical benefit to evaluate the effects of chinese medicine on the treatment of cancer?

Ping-ping Li1.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20131028     DOI: 10.1007/s11655-010-0009-z

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


× No keyword cloud information.
  1 in total

1.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

  1 in total
  3 in total

Review 1.  The role of Chinese medicine in clinical oncology.

Authors:  Yan Sun
Journal:  Chin J Integr Med       Date:  2013-10-14       Impact factor: 1.978

Review 2.  Plant-based Rasayana drugs from Ayurveda.

Authors:  Subramani Paranthaman Balasubramani; Padma Venkatasubramanian; Subrahmanya Kumar Kukkupuni; Bhushan Patwardhan
Journal:  Chin J Integr Med       Date:  2011-03-09       Impact factor: 1.978

Review 3.  Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine.

Authors:  Dong Xue; Ping-Ping Li
Journal:  Chin J Integr Med       Date:  2011-02-27       Impact factor: 1.978

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.